Investigating GB7208: An Oral, CNS-Penetrant, Irreversible BTK inhibitor for the Treatment of Neuroinflammatory Diseases

Time: 4:00 pm
day: Day One


  • Learn how BTK inhibitors are actively being explored in inflammatory diseases
  • Discover how they are characterized by modest selectivity and/or limited central nervous system (CNS) penetrance
  • Assess GB7208, an orally available, selective, irreversible small molecule BTK inhibitor which has been selected based on its potency, specificity, and high brain penetrance in preclinical models